Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland.

Autor:	Pazgan-Simon M; Department of Infectious Diseases, Regional Specialistic Hospital, 50-149 Wrocław, Poland., Jaroszewicz J; Department of Infectious Diseases and Hepatology, Medical University of Silesia in Katowice, 41-902 Bytom, Poland., Simon K; Department of Infectious Diseases, Regional Specialistic Hospital, 50-149 Wrocław, Poland.; Department of Infectious Diseases and Hepatology, Wroclaw Medical University, 51-149 Wrocław, Poland., Lorenc B; Department of Infectious Diseases, Pomeranian Center of Infectious Diseases, University of Gdansk, 80-210 Gdańsk, Poland., Sitko M; Department of Infectious and Tropical Diseases, Collegium Medicum, Jagiellonian University, 30-252 Kraków, Poland., Zarębska-Michaluk D; Department of Infectious Disease, Voivodeship Hospital, Jan Kochanowski University, 25-369 Kielce, Poland., Dybowska D; Department of Infectious Diseases and Hepatology, Faculty of Medicine, Nicolaus Copernicus University, 87-100 Bydgoszcz, Poland., Tudrujek-Zdunek M; Department of Infectious Diseases, Medical University of Lublin, 20-059 Lublin, Poland., Berak H; Hospital for Infectious Diseases, Warsaw Medical University, 02-091 Warszawa, Poland., Mazur W; Clinical Department of Infectious Diseases, Medical University of Silesia, 40-055 Chorzów, Poland., Klapaczyński J; Department of Internal Medicine and Hepatology, Central Clinical Hospital of Internal Affairs and Administration, 02-241 Warszawa, Poland., Janczewska E; Department of Basic Medical Sciences, School of Public Health in Bytom, Medical University of Silesia, 40-055 Bytom, Poland.; ID Clinic, Hepatology Outpatient Department, 41-400 Mysłowice, Poland., Parfieniuk-Kowerda A; Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15-540 Białystok, Poland., Flisiak R; Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15-540 Białystok, Poland.
Jazyk:	angličtina
Zdroj:	Journal of personalized medicine [J Pers Med] 2023 Jul 09; Vol. 13 (7). Date of Electronic Publication: 2023 Jul 09.
DOI:	10.3390/jpm13071111
Abstrakt:	Introduction: In Poland, active HCV infection affects between 0.4 and 0.5% of the population, i.e., about 150,000 people, while the number of patients with epilepsy is estimated to be 350,000-400,000. Currently available antiviral therapies show little interaction with neurological drugs. The aim of our study was to evaluate the effectiveness and safety of the treatment of chronic HCV infection in patients with coexisting epilepsy. Methods: A total of 184 epilepsy patients were selected from the group of 10,152 HCV-infected patients treated for HCV infection within the Epiter-2 database from 2015 to 2018. Comparing the effectiveness and safety of anti-HCV regimens between the patients with comorbid epilepsy and 3573 patients without comorbidities was our study's objective. Results: The effectiveness of anti-HCV treatment was high in both the sample and the control group. No statistically significant SVR difference was observed between the sample group, with ITT = 93.5% and mITT = 95.5%, and the control group, with ITT = 95.2% and mITT = 97.5%, regardless of the genotype and the stage of liver disease at the start of therapy. The treatment was safe in patients with epilepsy. Conclusions: The effectiveness and safety of HCV treatment in patients with epilepsy are comparable to those of patients with no significant comorbidities.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu